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Background: Urokinase-type plasminogen activator (uPA)
and its inhibitor (PAI-1) play essential roles in tumor inva-
sion and metastasis. High levels of both uPA and PAI-1 are
associated with poor prognosis in breast cancer patients. To
confirm the prognostic value of uPA and PAI-1 in primary
breast cancer, we reanalyzed individual patient data pro-
vided by members of the European Organization for Re-
search and Treatment of Cancer–Receptor and Biomarker
Group (EORTC-RBG). Methods: The study included 18
datasets involving 8377 breast cancer patients. During fol-
low-up (median 79 months), 35% of the patients relapsed
and 27% died. Levels of uPA and PAI-1 in tumor tissue
extracts were determined by different immunoassays; values
were ranked within each dataset and divided by the number
of patients in that dataset to produce fractional ranks that
could be compared directly across datasets. Associations of
ranks of uPA and PAI-1 levels with relapse-free survival
(RFS) and overall survival (OS) were analyzed by Cox mul-
tivariable regression analysis stratified by dataset, including
the following traditional prognostic variables: age, meno-
pausal status, lymph node status, tumor size, histologic
grade, and steroid hormone-receptor status. All P values
were two-sided. Results: Apart from lymph node status, high
levels of uPA and PAI-1 were the strongest predictors of
both poor RFS and poor OS in the analyses of all patients.
Moreover, in both lymph node-positive and lymph node-
negative patients, higher uPA and PAI-1 values were inde-
pendently associated with poor RFS and poor OS. For (un-
treated) lymph node-negative patients in particular, uPA
and PAI-1 included together showed strong prognostic abil-
ity (all P<.001). Conclusions: This pooled analysis of the
EORTC-RBG datasets confirmed the strong and indepen-
dent prognostic value of uPA and PAI-1 in primary breast
cancer. For patients with lymph node-negative breast can-
cer, uPA and PAI-1 measurements in primary tumors may
be especially useful for designing individualized treatment
strategies. [J Natl Cancer Inst 2002;94:116–28]
Breast cancer is the most common malignancy in women in
the Western world. To improve the survival of patients with
primary breast cancer, adjuvant systemic treatment aimed at the
eradication of occult metastases has been shown to be beneficial
(1). For patients with lymph node-negative disease, however, the
clinical benefits of adjuvant systemic treatment are relatively
small because primary locoregional treatment cures 60%–70%
of these patients. As a result, a large number of patients would
be subjected to unnecessary and toxic side effects were adjuvant
therapy to be given to all breast cancer patients. To avoid a
burdening of patients not in need of systemic adjuvant treatment,
strong prognostic markers are warranted to distinguish between
patients with low and high risks of disease recurrence. The use
of traditional prognostic factors, such as age, menopausal status,
tumor size, tumor grade, and steroid hormone-receptor status, is
not sufficient to make such a classification.
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To facilitate refinement of risk-adapted individualized treat-
ment, major effort has been devoted to the study of factors that
govern tumor spread and metastasis. From these studies, it has
become clear that the ability of cancer cells to invade the extra-
cellular matrix, to intravasate into lymphatics and blood vessels,
and to form metastases at distant sites depends on the coordi-
nated interaction of two main protease systems, the matrix me-
talloproteinase and the plasminogen activator systems. The latter
system comprises the serine protease urokinase-type plasmino-
gen activator (uPA), its receptor (uPAR, CD87), and its main
inhibitor (PAI-1). These components play a central role in the
processes leading ultimately to the development of metastases
[for reviews, see references (2–4)]. Plasminogen activation re-
sults in the formation of the broad-spectrum serine protease
plasmin, which in turn activates the proenzyme of uPA to pro-
teolytic active uPA and is the activator of several matrix metal-
loproteinases (2–5). When compared with normal tissues, uPA,
uPAR, and PAI-1 all have been shown to be at increased levels
in malignant solid tumors in a variety of human cancers, includ-
ing breast cancer (2–4). As early as 1988, elevated uPA levels in
primary breast tumor tissue were shown to be associated with a
poor prognosis of the patient (6). In the early 1990s, it became
evident that high antigen levels of PAI-1 in primary breast tu-
mors also were associated with a poor prognosis (7). This find-
ing of a relationship between a protease inhibitor and an unfa-
vorable prognosis was initially surprising but is now explained
by the crucial role of PAI-1 in tumor cell adhesion, cell migra-
tion, and angiogenesis (8–10). Following the initial reports (6,7),
many independent studies have demonstrated that elevated tu-
mor antigen levels of uPA and PAI-1 are associated with poor
disease outcome in breast cancer [for reviews, see references
(2–4,11,12)]. Furthermore, it has been shown that high tumor
levels of uPA and PAI-1 predict a poor outcome for patients who
were treated with tamoxifen for advanced disease (13).
The main purpose of this study was to investigate whether the
prognostic impact of uPA and PAI-1, as published in different
reports from various authors, could be confirmed by a reanaly-
sis, conducted in a uniform manner, of the individual patient
data. To this end, the European Organization for Research
and Treatment of Cancer–Receptor and Biomarker Group
(EORTC-RBG) performed a pooled analysis with the use of 18
datasets originating from nine European countries. The prognos-
tic relevance of uPA and PAI-1 in the analyses of relapse-free
survival (RFS) and overall survival (OS) was studied for all
patients and in subgroups of lymph node-negative and lymph
node-positive patients by stratified Cox multivariable regression
analysis including the traditional prognostic factors.
METHODS
Datasets
The members of the EORTC-RBG proposed to share their
data on uPA and/or PAI-1 levels in primary breast cancer tu-
mors, on classical factors, and on the follow-up information. All
centers with published (14–25) (n  11) and unpublished (n 
7) datasets agreed to participate and sent their data to Rotterdam
for statistical reanalysis. All published studies reported on the
prognostic value of uPA and/or PAI-1. All of the participating
laboratories are involved in ongoing quality-assurance programs
for measurement of biologic variables in tumor tissue (26). Stud-
ies were approved by the local review boards. The following
inclusion and exclusion criteria were used: 1) All patients un-
derwent primary surgery for breast cancer; 2) surgery took place
before January 1, 1996; 3) there was no distant spread at or
within 1 month of surgery; 4) patients with residual disease
diagnosed within 1 month after primary surgery were excluded;
5) patients with noninvasive breast cancer or those who received
neoadjuvant therapy were excluded; 6) male breast cancer pa-
tients and female patients who previously experienced another
cancer (except basal cell skin cancer or early-stage cervical can-
cer stage Ia/Ib) and male breast cancer patients were excluded;
7) biochemical variables were determined in primary tumor tis-
sue extract; and 8) uPA and PAI-1 antigen levels were deter-
mined by immunoassays. Staging of the tumors was according to
the International Union Against Cancer TNM classification (27).
Patients with missing values for postsurgical histopathologic tu-
mor size (pT), lymph node status, and/or both estrogen receptor
(ER) and progesterone receptor (PgR) status and/or both uPA
and PAI-1 were excluded.
Of the 8377 patients included, the dates of primary surgery
ranged from September 1978 through December 1995. The pa-
tients were born between November 1891 and September 1969.
Of the 18 cooperating laboratories, 17 were able to provide data
for the analysis of uPA, and 15 provided data for PAI-1. For the
datasets labeled A through R (see Fig. 2), the levels of uPA and
PAI-1 were determined in either cytosolic tumor extracts
(datasets A–D and K–Q) or Triton X-100-treated tumor extracts
(datasets E–J and R). All assays used were commercially avail-
able immunoassays. Enzyme-linked immunosorbent assay
(ELISA) kits were obtained from American Diagnostica, Inc.
(Greenwich, CT; datasets A–I), Monozyme (Horsholm, Den-
mark; datasets P [only for PAI-1] and Q), and Oncogene Science
(Cambridge, MA; dataset R). Luminometric Immuno Assay
(LIA) kits were obtained from AB Sangtec Medical (Bromma,
Sweden; datasets M–O and P [only for uPA]), and an in-house
assay was obtained as described (datasets J–L) (28). The protein
assays used for the various datasets consisted of Bio-Rad (Her-
cules, CA; datasets A, D, F, L, M, Q, and R), Pierce (Rockford,
IL; datasets B, C, E, and G–J), or according to Lowry et al. (29;
datasets K and N–P). With the use of these various ELISAs,
LIA, and protein assays, it was found in the different datasets
that median levels of uPA ranged from 0.2 to 5.1 ng/mg of
protein and that for PAI-1 they ranged from 1.3 to 26.7 ng/mg
of protein. These wide ranges of median values highlighted the
need to model the underlying biologic relationship between uPA
and PAI-1 measurements in different datasets so as to allow a
uniform analysis, which was accomplished by introducing frac-
tional ranks as explained below. Histologic characteristics of the
tumors, patients’ ages, and adjuvant treatments are listed in
Table 1. Three percent of the patients were less than 35 years
old, and 40% were premenopausal. Forty-four percent of the
patients had small tumors (pT1), and 56% were lymph node
negative. The histologic grade of one third of the patients was
unknown. Forty-five percent of the patients received some form
of systemic adjuvant treatment. Thirty-five percent (n  2955)
of the patients experienced disease recurrence, and 27% (n 
2254) of the patients died within 10 years.
Statistical Analysis
Relationships between uPA and PAI-1 as well as patient and
tumor characteristics were investigated with the use of nonpara-
metric methods, i.e., Spearman rank correlations for continuous
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variables and the Wilcoxon rank-sum test or the Kruskal–Wallis
test for ordered variables. In the latter tests, patient and tumor
characteristics were used as grouping variables. A nonparamet-
ric test for trend was used when appropriate. For all survival
analyses, a Cox proportional hazards model was used. The like-
lihood ratio test was used to test for differences between models.
The endpoint for RFS was defined as any recurrence of breast
cancer or contralateral breast cancer; for OS, it was defined as
death from any cause. Patients who died without relapse were
censored at the last date of follow-up for the analysis of RFS.
Patients with events after 120 months were censored at 120
months. The rationale was that, after 10 years of observation,
patients frequently are redirected to their general practitioner for
checkups and mammography and cease to be patients of the
outpatient breast cancer clinic. This would have an impact on the
availability and validity of follow-up data after 10 years.
The median follow-up of patients alive ranged from 46
months to more than 120 months in the different datasets. Five
datasets had a median follow-up of patients alive of less than
60 months (46, 48, 53, 55, and 58 months, respectively). A base
model was defined with the use of traditional prognostic factors
and adjuvant systemic therapy. Age was included as a linear
variable for both premenopausal and postmenopausal age com-
bined with an indicator variable for menopausal status. This
proved to be the best way of introducing age into the model, as
it allows for the sharp decrease in hazard rates with age for the
youngest patients. As for tumor status, pT3 and pT4 were treated
as one category because the estimates from the Cox regression
were similar in univariate and multivariable analyses with RFS
as the endpoint. Lymph node status was the number of involved
lymph nodes categorized as 0, 1–3, 4–10, and more than 10. Low
hormone-receptor status was defined as either both ER low and
PgR low or either ER low or PgR low and the other unknown;
high hormone-receptor status was defined as at least one of ER
or PgR high. The cutoff points as determined by each individual
laboratory for its dataset in defining high and low for ER and
PgR, or the categorization as it was provided, was used. Histo-
logic grade was included as well differentiated (grade I), mod-
erately differentiated (grade II), undifferentiated (grade III), or
unknown. Grade III was used as the reference category in the
survival analyses. Adjuvant therapy was included as none, un-
known, or any therapy. Some datasets did not have sufficient
numbers of events to allow a multivariable analysis. Cox uni-
variate and multivariable regression analyses with either RFS or
Table 1. Patient and tumor characteristics
Factor
No. of
patients %
uPA PAI-1
Total/high† % high† Two-sided P Total/high† % high† Two-sided P
Total 8377 100 8175/4086 50 6682/3337 50
Age in categories, y .55‡ .03‡
<35 243 3 239/116 49 212/118 56
35–55 3799 45 3720/1841 49 3104/1485 48
56–70 3084 37 2998/1546 52 2357/1192 51
>70 1251 15 1218/583 48 1009/542 54
Menopausal status .52§ .02§
Premenopausal 3338 40 3278/1618 49 2749/1336 49
Postmenopausal 5039 60 4897/2468 50 3933/2001 51
Tumor size <.001 <.001
pT1, 2 cm 3650 44 3540/1694 48 2857/1289 45
pT2, >2–5 cm 4120 49 4035/2131 53 3266/1760 54
pT3, >5 cm 444 5 438/180 41 407/204 50
pT4 163 2 162/81 50 152/84 55
Lymph nodes involved .61 <.001
0 4676 56 4497/2270 50 3662/1740 48
1–3 2092 25 2079/1005 48 1692/890 53
4–10 1166 14 1160/583 50 952/513 54
>10 443 5 439/228 52 376/194 52
Histologic grade <.001 <.001
I 583 7 530/209 39 439/157 36
II 2237 27 2156/1065 49 1811/866 48
III 2786 33 2728/1480 54 2490/1385 56
Unknown 2771 33 2761/1332 48 1942/929 48
Adjuvant treatment .44 <.001
No 4286 51 4127/2061 50 3844/1891 49
Unknown 320 4 320/145 45 44/20 45
Yes 3771 45 3728/1880 50 2794/1426 51
Steroid hormone-receptor status¶ <.001§ <.001§
Low 1697 20 1665/1052 63 1306/825 63
High 6680 80 6510/3034 47 5376/2512 47
*uPA  urokinase-type plasminogen activator; PAI-1  plasminogen activator inhibitor; pT  postsurgical histopathologic tumor size.
†Above the overall median rank (rescaled ranks pooled for all datasets) for all tumors with data on uPA (8175 patients) or PAI-1 available (6682 patients).
‡Spearman rank correlation.
§Mann–Whitney U test.
Kruskal–Wallis test, followed by a nonparametric test for trend when appropriate.
¶Low and high steroid hormone-receptor status as defined in the “Methods” section.
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OS as endpoint were used; the sets were pooled and stratified by
dataset. All multivariable analyses included the base model,
which was defined as all variables except uPA and PAI-1. The
proportional hazards assumption was checked on the full mod-
els. The assumption was not violated by uPA or PAI-1; however,
some traditional prognostic factors, especially hormone-receptor
status and lymph node status, did. Because the purpose of this
study was to show the prognostic impact of uPA and PAI-1, we
chose to keep the base model as defined. To visualize uPA and
PAI-1 in Kaplan–Meier curves, for each dataset, the uPA and
PAI-1 data were divided into fifths with the use of their 20th,
40th, 60th, and 80th percentiles. The log-rank test for trend was
used to test for differences.
Despite the use of different extraction and assay methods,
measurements are highly correlated (30–32); i.e., high levels of
uPA and PAI-1 with the use of one method are high according
to another method as well. However, because the method of
determination varied between laboratories, a common scale was
required. For each dataset, we ranked the uPA and PAI-1 mea-
surements and divided the ranks by the number of patients.
Thus, the uPA and PAI-1 levels were converted to fractional
ranks (between 0 and 1). In this way, equal fractional ranks are
comparable across datasets with different numbers of patients
included. Effectively, we assume that the use of different assays
did not influence the ranks of uPA and PAI-1 levels profoundly.
As an alternative to dichotomization in each dataset, ranking and
rescaling also have the advantage of allowing us to analyze uPA
and PAI-1 as continuous variables. The hazard ratios (HRs) for
the ranked variables represent the differences between the ex-
tremes. For a continuous variable, the hazard increases per unit
with the HR, which, in the case of fractional ranks, is the full
range from 0 to 1. For categorized variables, such as uPA and
PAI-1 when divided into fifths, dummy variables were intro-
duced. The lower fifth was considered the reference category.
The HRs for the remaining four groups were calculated com-
pared with the reference category.
The base model was used to investigate the best fit of ranked
uPA and PAI-1 in relation to RFS. The effect of ranked uPA and
PAI-1 was modeled with the use of spline regression and frac-
tional polynomials with relapse as the endpoint in a Cox pro-
portional hazards model, stratified by dataset, and adjusted for
the base model. For uPA, spline regression with four knots (0.2,
0.4, 0.6, and 0.8) showed the best fit. Fractional polynomials or
five knots in spline transformation did not result in a statistically
significantly better fit. The spline-transformed ranked uPA val-
ues, rescaled between 0 and 1, were used for survival analyses.
The ranks of PAI-1 did not need transformation because the
linear variable showed the best fit. For visualization of the in-
dividual datasets, the HRs and 95% confidence intervals (CIs)
corrected for the base model were presented as a forest plot (33).
The combined HR and its 95% CI were calculated with the use
of a random effects model (34). In random effects models, the
between-studies variance is estimated and used to modify the
weight used to calculate the summary estimate. It is assumed
that, in addition to sampling variation, the true effect varies
between studies. The random effects model will in general be
more conservative (wider CIs) than the fixed effects model,
which is based on the assumption that the true effect does not
differ between studies. Using the random effects model, we
estimated a mean effect (of the differing effects) around which
the true effect is assumed to vary.
With the use of the base model and the final transformations
of uPA and PAI-1, interactions were investigated between the
prognostic variables (age and menopausal status, tumor size,
lymph node status, hormone-receptor status, histologic grade,
and adjuvant treatment) and uPA or PAI-1 with the use of the
Cox proportional hazards model, stratified by dataset with RFS
as the endpoint. For all interactions, a P value less than .01 was
considered statistically significant. The results suggest the analy-
sis of the subsets of lymph node-negative and lymph node-
positive patients. To visualize the prognostic value of uPA and
PAI-1 in Kaplan–Meier curves for lymph node-negative and
lymph node-positive patients, prognostic scores were calculated
with both uPA and PAI-1 added to the base model and stratified
for datasets. The scores (exponentiated linear prediction) then
were divided into fifths (i.e., with the use of the 20th, 40th, 60th,
and 80th percentiles). All statistical analyses were performed
with the use of Stata Statistical Software (release 6.0; Stata
Corp., College Station, TX). Two-sided P values are given.
RESULTS
Associations of uPA and PAI-1 With Patient and Tumor
Characteristics
The patient and tumor characteristics of all 8377 patients
included in the pooled analysis are presented in Table 1. The
relationships between uPA (8175 patients) or PAI-1 (6682 pa-
tients) and patient and tumor characteristics are shown. The uPA
and PAI-1 data are expressed as percentages of tumors above the
median rank value of 0.5. There were no statistically significant
relationships between uPA and age, menopausal status, or lymph
node status. PAI-1 values were correlated with age and were
found to be higher in postmenopausal and lymph node-positive
patients. The slightly higher PAI-1 levels in patients who re-
ceived adjuvant treatment compared with those who did not are
probably a reflection of the association between treatment and
lymph node status. Both the Spearman correlation coefficient
between PAI-1 and age and its P value were .03. We considered
this correlation and the relationship between PAI-1 and meno-
pausal status to be of no clinical relevance. uPA and PAI-1 were
positively correlated with histologic grade, negatively correlated
with hormone-receptor status, and found to be highest in pT2
and pT4 tumors. The Spearman correlation coefficient between
the ranked uPA and PAI-1 values was .57 (P<.001; n  6480).
Survival Analysis in All Patients as a Function of uPA and
PAI-1 Status
Relapse-free survival. In Cox univariate analysis for RFS
(data not shown), young premenopausal age, postmenopausal
status, tumor size, number of lymph nodes involved, low steroid
hormone-receptor level, and poor grade were all statistically
significantly associated with a poor disease outcome (all
P<.001). Adjuvant treatment was associated with a poor RFS as
a result of its association with poor prognostic features such as
young premenopausal age and axillary lymph node involvement
at diagnosis. Higher values of uPA and PAI-1 as continuous
values were associated with a poor RFS (2  189.5 and 247.1,
respectively; df  1). For visualization of the associations
of uPA and PAI-1 with RFS in Kaplan–Meier curves (Fig. 1,
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A and B), both variables were divided into fifths (F1 through F5)
(2  176.2 for uPA and 2  228.4 for PAI-1; df  4; both
P<.001).
In Cox multivariable analysis for RFS, all classical prognos-
tic variables were statistically significantly associated with RFS
(all P<.001), with adjuvant treatment now being a favorable
prognostic factor as a result of the inclusion of the traditional
prognostic variables. This multivariable model, with adjuvant
treatment included, was defined as the base model (Table 2). The
HRs and 95% CIs corrected for the base model of each indi-
vidual dataset are shown in Fig. 2. The areas of the boxes are
inversely proportional to the variance and, as such, are related to
the number of patients included in the individual datasets (33).
Fig. 2, A, shows RFS for ranked uPA; Fig. 2, B, shows RFS for
ranked PAI-1. For uPA, six of the 17 CIs include the value 1; for
PAI-1, seven of 15 CIs include the value 1, implying no statis-
tical significance (P>.05) for those (mainly small) datasets. Not
all datasets had sufficient numbers of events. Only one HR is
estimated to be less than 1 (set J with 88 patients in Fig. 2, A).
The diamonds present the combined estimates of the HRs and
95% CIs. Adding uPA and PAI-1 separately as continuous vari-
ables to the base model for RFS resulted in an increase in 2
(2) of 168.5 and 176.1 (both with 1 df; P<.001). For both, the
HR (95% CI) was 2.58 (2.24 to 2.97) (Table 3). When uPA and
PAI-1 were added simultaneously as continuous variables to the
base model, stratified by dataset, their respective HRs and
95% CIs for RFS were 1.70 (1.42 to 2.04) and 2.00 (1.69 to
2.37). This resulted in a 2 of 203.6 with one additional df
(df  2). Because an increase of 3.84 for one more df is nec-
essary to obtain statistical significance, the increase in 2 of
Fig. 1. Relapse-free survival (A and B) and overall survival
probabilities (C and D) as a function of urokinase-type plas-
minogen activator (uPA) (A and C) and its inhibitor (PAI-1)
(B and D) values. For each dataset, original uPA and PAI-1
values were divided into five groups (F1–F5) with the use of
their 20th, 40th, 60th, and 80th percentiles. Events indicate
the number of failures in each group. Patients at risk at 0,
30, 60, 90, and 120 months are indicated. The survival
probabilities (and their 95% confidence intervals) at 60 and
120 months, respectively, are as follows: panel A—curve
F1  75.6 (73.4 to 77.7) and 63.2 (60.0 to 66.2), curve
F2  70.7 (68.3 to 73.0) and 59.2 (55.9 to 62.2), curve F3
 69.7 (67.3 to 72.0) and 55.2 (51.8 to 58.4), curve F4 
66.8 (64.3 to 69.1) and 52.8 (49.3 to 56.2), and curve F5 
55.6 (53.0 to 58.1) and 42.7 (39.4 to 46.0); panel B—curve
F1  76.2 (73.7 to 78.5) and 61.5 (57.6 to 65.2), curve F2
 72.4 (69.7 to 74.8) and 56.6 (52.7 to 60.3), curve F3 
65.6 (62.8 to 68.2) and 52.3 (48.4 to 56.0), curve F4  59.2
(56.3 to 61.9) and 44.2 (40.4 to 47.9), and curve F5  52.6
(49.7 to 55.3) and 38.6 (34.8 to 42.3); panel C—curve F1
 86.8 (85.0 to 88.4) and 70.8 (67.7 to 73.8), curve F2 
82.1 (80.0 to 84.0) and 66.3 (63.0 to 69.3), curve F3  79.6
(77.5 to 81.6) and 63.6 (60.3 to 66.6), curve F4  77.5
(75.3 to 79.5) and 62.0 (58.8 to 65.0), and curve F5  69.1
(66.6 to 71.4) and 50.8 (47.5 to 54.0); and panel D—curve
F1  87.4 (85.5 to 89.2) and 71.1 (67.1 to 74.7), curve F2
 83.1 (80.9 to 85.1) and 65.8 (62.0 to 69.3), curve F3 
78.6 (76.2 to 80.8) and 58.1 (54.1 to 61.9), curve F4  73.9
(71.4 to 76.3) and 54.5 (50.7 to 58.1), and curve F5  62.2
(59.3 to 64.8) and 44.8 (41.0 to 48.6). HR  hazard ratio.
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27.5 (203.6 minus 176.1) implies that both factors indepen-
dently added to the prognostic strength provided by the tradi-
tional prognostic factors, of which nodal status is the strongest
factor (Table 2). Thus, the model containing both uPA and
PAI-1 is preferable over a model with only one of these factors
(Table 3).
Overall survival. In the Cox univariate and multivariable
analyses for OS, the same factors that were of prognostic value
in the analysis of RFS showed statistically significant associa-
tions in the same directions (all P<.001). Again nodal status is
the strongest prognostic factor in the model (data not shown). As
in the analysis for RFS, in the multivariable analysis for OS it
was shown that both uPA and PAI-1 were independent of the
traditional prognostic factors included in the base model and,
furthermore, that inclusion of both factors resulted in a better fit
(2  212.9; df  2) than that achieved with the inclusion of
either factor alone (2  149.5 and 192.4 for uPA and PAI-1,
respectively; df  1) (Table 3). The Kaplan–Meier curves pre-
sented in Fig. 1, C and D, illustrate the relationships of uPA and
PAI-1 as categorical variables divided into fifths (2  171.9
and 2  259.4, [df  4], respectively; both P<.001).
Interaction. The prognostic variables included in the base
model were tested separately for interaction with uPA and PAI-
1, with relapse as the endpoint. Significant interactions were
observed between uPA and PAI-1 values with lymph node status
(2  13.6, df  3, and P  .004, and 2  14.4, df  3, and
P  .002, respectively) and of uPA with tumor size (2  9.3,
df  2, and P  .009). The other interactions tested were not
statistically significant, including those between uPA and PAI-1
(2  1.9, df  1, and P  .17). The interaction of lymph
node status with uPA and PAI-1 suggested the analysis of the
prognostic value of uPA and PAI-1 in the clinically important
subgroups of lymph node-negative and lymph node-positive
patients.
Fig. 1. Continued.
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Survival Analysis as a Function of uPA and PAI-1 Status
According to Lymph Node Status of the Patients
Lymph node-negative patients. Until recently, systemic ad-
juvant treatment for lymph node-negative patients was not stan-
dard practice in many European countries. Of the 4676 lymph
node-negative patients in the pooled dataset, 3362 (72%) did not
receive systemic adjuvant therapy. To study the impact of uPA
and PAI-1 on RFS and OS, we analyzed the prognostic value of
uPA and PAI-1 in all 3483 lymph node-negative patients for
whom both uPA and PAI-1 data were available. Table 4 (upper
part) shows the results of adding uPA and PAI-1, separately or
combined, to the base model for RFS. Except for the lack of a
statistically significant association of steroid hormone-receptor
status and adjuvant treatment with RFS, all traditional prognos-
tic variables were statistically significantly associated with RFS
and OS. uPA and PAI-1 were statistically significantly associ-
ated with poor RFS (Table 4, upper part) when added separately
to the base model (all P<.001). Furthermore, the addition of both
uPA and PAI-1 to the base model for RFS resulted in a statis-
tically significantly better fit (2  116.8; df  2) than the
addition of either factor alone (2  94.8 for uPA, 2  83.1
for PAI-1; df  1). It is remarkable that the 2 associated with
the simultaneous addition of uPA and PAI-1 was of a similar
magnitude as the 2 of 129.3 of the base model with all of the
traditional prognostic factors. In the analysis for OS, the addition
of uPA and PAI-1 together resulted in a 2 of 95.3 (df  2).
This compared with 69.2 (df  1) for uPA and 74.2 (df  1) for
PAI-1, implying a statistically significantly better fit after the
addition of both UPA and PAI-1 in the analysis for OS, as well.
The HRs and 95% CIs were not different when the multivari-
able-stratified analysis for RFS and OS were restricted to the
2864 lymph node-negative patients who had not received adju-
vant treatment and for whom both uPA and PAI-1 data were
available. When both uPA and PAI-1 were added to the base
model for RFS, a statistically significantly better fit was ob-
served (2  94.0; df  2) than that observed after the addi-
tion of either factor alone (2  76.6 for uPA, and 2  66.5
for PAI-1; df  1) (Table 4, middle part). Similar results were
obtained in the analysis for OS (uPA and PAI-1 together, 2 
81.6, and df  2; uPA or PAI-1 alone, 2  57.5 and 65.6,
respectively, and df  1).
To show categorized results for uPA and PAI-1 in lymph
node-negative patients, we calculated a prognostic score based
on the estimates from the multivariable analysis for RFS for all
lymph node-negative patients (Table 4, upper part). For visual-
ization in Kaplan–Meier curves, the prognostic score was di-
vided into fifths with the use of the 20th, 40th, 60th, and 80th
percentiles. In the analysis for RFS, based on the prognostic
score for all 3483 lymph node-negative patients with both uPA
and PAI-1 data available, the difference in 10-year RFS between
the lowest and highest risk groups was 34.5% (Fig. 3, A). In the
analysis for OS, the survival difference between the extreme-risk
groups was 28.2% at 10 years (Fig. 3, C). For the 2864 untreated
Table 2. Multivariable stratified Cox regression analysis for relapse-free survival: base model*
Factor
No. of
patients Events HR† 95% CI† 2 df Two-sided P‡
Total 8377 2955 1173 14 <.001
Age and menopausal status§ 74.6 3 <.001
Age premenopausal 3338 1258 0.70 0.64 to 0.76
Age postmenopausal 5039 1697 0.96 0.91 to 1.02
Postmenopausal vs. premenopausal 1.35 1.18 to 1.54
Tumor size, cm 98.8 2 <.001
2 3650 953 1
>2–5 4120 1651 1.43 1.31 to 1.55
>5 607 351 1.79 1.57 to 2.04
Lymph nodes involved 626.5 3 <.001
0 4676 1211 1
1–3 2092 760 1.86 1.67 to 2.08
4–10 1166 662 3.27 2.91 to 3.66
>10 443 322 5.54 4.81 to 6.39
Steroid hormone-receptor status¶ 24.6 1 <.001
Low 1697 689 1
High 6680 2266 0.79 0.73 to 0.87
Histologic grade 71.4 3 <.001
III 2786 1259 1
Unknown 2771 959 0.79 0.71 to 0.89
II 2237 645 0.73 0.66 to 0.81
I 583 92 0.48 0.38 to 0.60
Adjuvant therapy 66.7 2 <.001
No 4286 1516 1
Unknown 320 80 0.98 0.70 to 1.37
Yes 3771 1359 0.66 0.60 to 0.73
*Stratified for dataset.
†HR  hazard ratio; CI  confidence interval.
‡Likelihood ratio test.
§Age and menopausal status combined; age tested separately for premenopausal and postmenopausal patients.
Postsurgical histopathologic tumor size pT3 and pT4 combined.
¶Low and high steroid hormone-receptor status as defined in the “Methods” section.
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lymph node-negative patients, the differences in 10-year RFS
and OS between the lowest and highest risk groups were of
similar magnitude: 35.4% and 28.1%, respectively (Kaplan–
Meier curves not shown).
Lymph node-positive patients. For the 2997 lymph node-
positive patients with both uPA and PAI-1 data available, the
results of adding uPA and PAI-1 separately or together to the
base model for RFS are shown in Table 4 (bottom part). All
traditional prognostic variables were statistically significantly
associated with RFS and OS. Furthermore, uPA and PAI-1 were
statistically significantly associated with poor RFS (Table 4,
bottom part) and OS when added separately to the base model
(for all, P<.001). In contrast to lymph node-negative patients,
for lymph node-positive patients, the addition of both uPA
and PAI-1 to the base model in the analysis for RFS did not
result in a better fit (2  88.4; df  2) than the addition of
either factor alone (2  52.5 for uPA, and 2  87.1 for
PAI-1; df  1) (Table 4, bottom part). However, in the OS
analysis, the simultaneous addition of uPA and PAI-1 resulted in
a better fit (2  121.4; df  2), compared with the addition
of uPA (2  77.0; df  1) or PAI-1 alone (2  105.9;
df  1).
A prognostic score was calculated for lymph node-positive
patients also. In the analysis for RFS, the difference in 10-year
Fig. 2. Multivariable analysis for relapse-free survival (RFS) as a function of
urokinase-type plasminogen activator (uPA) (A) and its inhibitor (PAI-1) (B) per
dataset presented as a forest plot. All data are corrected for the base model,
including age and menopausal status, tumor size, lymph node status, steroid
hormone-receptor status, histologic grade, and adjuvant treatment. For each
dataset, the hazard ratio (HR) of transformed ranked uPA or ranked PAI-1 values
is plotted as a solid square, its area being inversely proportional to the variance
of the estimated effect, and its 95% confidence interval (CI) is plotted as a
horizontal line. Individual patient data were obtained from both published [in
whole or in part; A (14), C (15), D (16), F (17), I (18), M (19), N (20), O (21),
P (22), Q (23,24), and R (25)] and unpublished (B, E, G, H, J, K, and L) datasets.
Diamond represents the combined random effects estimate (middle of the dia-
mond) and its 95% CI (extremes of the diamond) of the combined estimates
adjusted for the base model.
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RFS between the lowest and highest risk groups was 41.4% (Fig.
3, B). In the analysis for OS, the survival difference between the
extreme-risk groups defined by the prognostic score was 45.9%
at 10 years (Fig. 3, D).
DISCUSSION
Identification of those prognostic and predictive factors that
reflect the biology of breast cancer is important for refining our
assessment of prognosis and the selection of patients who may
benefit from adjuvant systemic therapy. In this respect, numer-
ous cell biologic factors have been studied in the past decade.
Except for the well-established clinical utility of steroid hor-
mone receptors, ER and PgR, many studies on prognostic factors
are hampered by inconsistent results. They are often inconclu-
sive as a result of small numbers of patients and heterogeneity of
the studies with respect to patient populations and laboratory
techniques used. Therefore, guidelines have been established for
the assessment of the clinical utility of prognostic factors
(35,36). The studies reporting the impact of uPA and PAI-1 on
primary breast cancer prognosis all have shown an unfavorable
Table 3. Multivariable stratified analysis for relapse-free survival and overall survival as a function of urokinase-type plasminogen
activator (uPA) and its inhibitor PAI-1
Factor* No. of patients Events HR† 95% CI† 2 df Two-sided P‡
Relapse-free survival
uPA§ 8175 2903 2.58 2.24 to 2.97 168.5 1 <.001
PAI-1§ 6682 2543 2.58 2.24 to 2.97 176.1 1 <.001
uPA + PAI-1 6480 2491 203.6 2 <.001
uPA 1.70 1.42 to 2.04
PAI-1 2.00 1.69 to 2.37
Overall survival
uPA§ 8175 2228 2.73 2.33 to 3.19 149.5 1 <.001
PAI-1§ 6682 1960 3.12 2.65 to 3.67 192.4 1 <.001
uPA + PAI-1 6480 1934 212.9 2 <.001
uPA 1.77 1.44 to 2.16
PAI-1 2.34 1.93 to 2.83
*uPA and its inhibitor, PAI-1, added alone or together, as continuous variable, to the base model presented in Table 2. Hazard ratios represent the difference
between the extreme fractional ranks of uPA or PAI-1 levels (i.e., a fractional rank of 1 compared with a fractional rank of 0).
†HR  hazard ratio; CI  confidence interval.
‡Likelihood ratio test.
§uPA or PAI-1 added alone.
uPA and PAI-1 added togther.
Table 4. Multivariable stratified analysis for relapse-free survival in lymph node subgroups of patients*
Factor† No. of patients Events HR‡ 95% CI‡ 2 df Two-sided P§
All lymph node-negative patients
Base model 3483 970 129.3 11 <.001
uPA 3.42 2.68 to 4.37 94.8 1 <.001
PAI-1 2.87 2.28 to 3.60 83.1 1 <.001
uPA + PAI-1¶ 116.8 2 <.001
uPA 2.37 1.78 to 3.16
PAI-1 1.90 1.45 to 2.49
Lymph node-negative patients without adjuvant treatment
Base model 2864 829 105.7 9 <.001
uPA 3.34 2.56 to 4.36 76.6 1 <.001
PAI-1 2.77 2.17 to 3.55 66.5 1 <.001
uPA + PAI-1¶ 94.0 2 <.001
uPA 2.34 1.71 to 3.21
PAI-1 1.86 1.39 to 2.48
Lymph node-positive patients
Base model 2997 1521 476.0 13 <.001
uPA 2.10 1.72 to 2.56 52.5 1 <.001
PAI-1 2.41 2.00 to 2.90 87.1 1 <.001
uPA + PAI-1¶ 88.4 2 <.001
uPA 1.34 1.06 to 1.71
PAI-1 2.05 1.64 to 2.56
*For patients for whom information on levels of both urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) are available.
†uPA and PAI-1 added alone or together as continuous variable to the base models (lymph node status not included in the base models for lymph node-negative
patients; adjuvant therapy not included in the base model for untreated lymph node-negative patients). Hazard ratios represent the difference between the extreme
fractional ranks of uPA or PAI-1 levels (i.e., a fractional rank of 1 compared with a fractional rank of 0).
‡HR  hazard ratio; CI  confidence interval.
§Likelihood ratio test.
uPA or PAI-1 added alone.
¶uPA and PAI-1 added together.
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clinical outcome with high levels of uPA and/or PAI-1, and
virtually all of the criteria set by the guidelines have been met
[for a review, see reference (12)]. More recently, it has been
proposed that, for acceptance of new tumor-associated markers
into clinical practice, studies should meet the Tumor Marker
Utility Grading System criteria for level of evidence 1 (LOE-1)
(37,38). According to these criteria, LOE-1 can be attained ei-
ther by a prospective high-powered study of a tumor-associated
marker or by a suitable meta-analysis of prospective or retro-
spective datasets (37,38). To substantiate the prognostic value of
uPA and PAI-1 for patients with primary breast cancer, two
LOE-1-type studies now have been carried out. The first is a
prospective clinical trial in lymph node-negative breast cancer
patients (39), and the second is the pooled analysis presented in
this article. This analysis is, to our knowledge, the first collabo-
rative study on tumor biologic markers in breast cancer with the
use of observational individual patient data.
In the various published studies on the prognostic signifi-
cance of uPA and PAI-1, different variables were included in the
final multivariable models, and often the numbers of events were
too low to be conclusive (12). In this pooled analysis of indi-
vidual patient data, we included the same variables and end-
points for all datasets. All analyses presented included the same
traditional prognostic variables, defined as the base model. Our
study population included the individual patient and laboratory
data provided by the members of the EORTC-RBG. The
EORTC-RBG designs and validates new laboratory assays and
interacts on an international basis. It is important that all member
laboratories are involved in quality-assurance programs for uPA
and PAI-1 (26,30).
The 18 datasets included in these analyses were heteroge-
neous with respect to the immunoassays used, the method of
tumor extraction, the protein determination, and the patient char-
acteristics. The first three of these differences were overcome in
part by transforming uPA and PAI-1 levels to fractional ranks
for all individual datasets, while the introduction of a base model
helped to decrease the heterogeneity between datasets as a result
of the patient characteristics.
For uPA, spline-transformed ranked values with four knots,
rescaled between 0 and 1, gave the best fit and were thus used in
the analyses; increasing the number of the knots or analyzing by
fractional polynomials did not result in a better fit. For PAI-1, no
further transformation of the ranks was necessary; the ranked
variable already provided the best fit. Note that, despite the
heterogeneity between the individual datasets, the multivariable
analysis with the use of ranked variables showed that the HRs
for relapse in the individual datasets all point in the same direc-
tion, with the exception of one small study of 88 patients. In the
various published studies on the prognostic value of uPA and/or
PAI-1 in primary breast cancer [for review, see reference (12)],
different subgroups were analyzed, such as lymph node-negative
and lymph node-positive patients, premenopausal and post-
menopausal patients, and steroid hormone-receptor subgroups of
patients. In this study, we corrected for these traditional prog-
nostic variables in the multivariable base model, including tumor
grade and adjuvant treatment. We found a statistically signifi-
cant interaction between uPA and PAI-1 with lymph node status
in the analysis for RFS that led us to further investigate the
subgroups of lymph node-negative and lymph node-positive pa-
tients. Analyzing subgroups ignores a large number of patients,
and there is the risk of running into low numbers of events
jeopardizing these analyses. For lymph node-negative and
lymph node-positive patients with both uPA and PAI-1 data
available, the numbers of events (970 and 1521, respectively)
were sufficient, assuming that we need 15 events per category of
a variable (40). In our final multivariable models, the required
numbers of events would amount to approximately 200 for the
lymph node-negative patients and 225 for the lymph node-
positive patients.
The results presented here on more than 8000 female patients
with primary breast cancer show unequivocally that high tumor
levels of uPA and PAI-1 are associated with poor RFS and OS.
Similar findings were observed in the clinically important sub-
groups of (untreated) lymph node-negative and lymph node-
positive breast cancer patients. In the multivariable RFS and OS
analyses of all patients, lymph node status was the strongest
prognostic variable, followed by levels of uPA and PAI-1 to-
gether. Adding both uPA and PAI-1 to the model showed an
effect twice as strong as tumor size or histologic grade, irrespec-
tive of the observed positive correlation between uPA and PAI-1
with size and grade of the tumor. Of particular interest was the
observation that, in multivariable RFS analyses of lymph node-
negative patients, the addition of uPA and PAI-1 together was of
a similar prognostic magnitude as the base model itself, with the
currently used prognostic factors included. When stratified by
dataset, a prognostic score for the full model, including both
uPA and PAI-1, distinguished between patients with a favorable
and an unfavorable prognosis (a 34.5% difference in RFS and a
28.2% difference in OS at 10 years between the extreme-risk
groups). In the most favorable 20% group of patients, at 10
years, the RFS and OS probabilities were 76.9% and 87.2%,
respectively. For patients in this low-risk group, some form of
adjuvant endocrine treatment could be considered, which may be
less beneficial for patients with high uPA and PAI-1 levels (13).
Some form of adjuvant chemotherapy could be offered to the
remaining lymph node-negative patients. In lymph node-positive
patients, with the use of the categorized prognostic score, one
fifth of the patients showed a relatively good prognosis (60.9%
RFS and 72.0% OS at 10 years). Furthermore, a large group of
patients (40%) with a particularly poor prognosis (<30% RFS)
could be identified. These latter patients could possibly benefit
from an aggressive form of adjuvant chemotherapy. Moreover,
patients with uPA-expressing tumors may be future candidates
for receiving drugs targeting the plasminogen activation system,
several of which are currently being developed and tested pre-
clinically (3,4).
Despite the heterogeneity of patient samples included and the
differences in tumor extraction methods and assays to measure
uPA and PAI-1 levels, this meta-analysis shows unequivocally
that high levels of uPA and PAI-1 are associated with a poor
prognosis in primary breast cancer. The information that can be
gained by measuring the tumor levels of uPA and PAI-1 is surely
beyond that which is obtained by the currently used classical
prognostic factors such as tumor stage and grade. This statement
also holds for the clinically important subgroups of (untreated)
lymph node-negative and lymph node-positive patients. In a rou-
tine setting, the levels of uPA and PAI-1 can be measured in as
little as 50 mg of tumor tissue, with the use of assays that can be
easily quality controlled (26) and standardized, making determi-
nations of uPA and PAI-1 tumor levels feasible for almost all
available primary breast tumors.
In spite of the strong data presented here, from this study, no
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recommendations for specific treatments for the various risk
groups of (subgroups of) patients can be made. To address this
issue, data from large, prospective, randomized (multicenter)
trials, where all laboratories use identical assays and are subject
to external quality control, are needed. To this end, lymph node-
negative patients stratified by their tumor uPA and PAI-1 levels
have been randomly assigned to receive chemotherapy or obser-
vation (39).
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